Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences
The live webcasts may be accessed under the Investors tab on and will be archived for 14 days.DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
都柏林，2024年11月25日 /PRNewswire/ -- 阿爾凱默斯（納斯達克：ALKS）今天宣佈管理層將參加兩場即將舉行的投資者會議。
7th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
第7屆Evercore ISI HealthCONx會議
日期/時間：2024年12月3日，星期二，上午10:25 ET（下午3:25 GMT）
Piper Sandler 36th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)
派傑投資第36屆醫療保健年會
日期/時間：2024年12月4日，星期三，下午4:00 ET（晚上9:00 GMT）
The live webcasts may be accessed under the Investors tab on and will be archived for 14 days.
直播網絡廣播可在投資者標籤下訪問，並將保存14天。
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at .
關於阿爾凱默斯公
阿爾凱默斯股份有限公司是一家專注於神經科學領域開發創新藥物的全球生物製藥公司。該公司擁有自主商業產品組合，用於治療酒精依賴、阿片類藥物依賴、精神分裂症和雙相情感障礙，以及在研發中開發用於神經系統疾病的臨床和臨床前候選藥物管線，包括睡病和特發性睡眠過度嗜眠症。總部設在愛爾蘭的阿爾凱默斯公司還在馬薩諸塞州設有公司辦公室和研發中心，在俄亥俄州設有製造設施。更多信息，請訪問阿爾凱默斯公司的網站。
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
阿爾凱默斯聯繫人：
傑米·康斯坦丁
投資者關係
+1 781 873 2402
SOURCE Alkermes plc
資料來源：阿爾凱默斯。
